Slides from Praful Mehta's presentation at Pharmaceutical Product Lifecycle Management Conference, London, 26th January 2012

1. Understanding Challenges Towards Effective Life Cycle Management (LCM) Pharmaceutical Product Lifecycle Management Conference London, 26 th January 2012 Praful Mehta, Senior Analyst, IHS

3. Overview of the Current Environment Overall it’s the perception of value which is undergoing a change in the industry

4. The Source of the Problem Note: Net innovation in a given year represents peak life cycle sales for each drug launched that year, less prior year sales for each drug expiring that year. Source: Goldman Sachs Research, FactSet, company data BOOM PERIOD LOST DECADE OF INNOVATION WILL PHARMA TAKE THE RED PILL OR BLUE PILL? Factor Xa’s Alzheimer's HDL Hepatitis C Vaccines Oncology Obesity Diabetes R&D Spend Poor capital allocation

5. The New Business Model The role of information has changed considerably from a peripheral point to a more integrated level The Biggest Challenge In a traditional blockbuster dependent model, information flows from one decision making entity to the next in peripheries but not within entities In a payer centric model, information flows between entities is much more rapid and ensures development of more effective solutions Payers and Specialists are the key decision makers Information Information Insight will play a deeper role in ensuring sustainability

9. How Does Integration Help You Make Better Decision in LCM? Multiple Secondary, Tertiary and Proprietary Sources Cross-country analysis of pricing, cost and sales data Analysis of treatment and dosing regimen Insights Dimensions of Data Collation * IHS Therapy Area Focused Services Help Clients Develop Meaningful Insights by Collating Information and Analysis in One Platform Analysis of trial endpoints, outcome parameters and cross country trial data Analysis of reimbursement, regulatory and policy environment Analysis of alliances, patents and financial data Drug / Disease Overview Clinical Trial Information Treatment Paradigm Pricing, Cost and Sales Information Regulatory and Reimbursement Information In 2011, almost two-thirds of LCM initiatives were shelved due to poor insights